MedTrace Logo

Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients

NCT02202239 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-07-28

No results posted yet for this study

Summary

To explore the effect of induction and maintenance of anesthesia with etomidate on hemodynamics and oxidative stress in diabetic patients.

Conditions

  • Hemodynamics
  • Oxidative Stress
  • Anesthesia

Interventions

DRUG

midazolam

Before induction, midazolam 0.05mg/kg will be injected intravenously.

DRUG

Penehyclidine Hydrochloride Injection

Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.

DRUG

Etomidate

Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.

DRUG

Propofol

Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.

DRUG

Fentanyl

During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.

DRUG

Cisatracurium Besilate

Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction. During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation.

DRUG

Remifentanil

Remifentanil will be injected continuously during maintenance of anesthesia.

DRUG

Sevoflurane

Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-08-31
Completion
2015-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202239 on ClinicalTrials.gov